Anaphylaxis not explained by a proved or presumptive cause or stimulus; accounts for ~30-60% of cases of anaphylaxis in adults and ~10% of cases in children
It becomes a diagnosis of exclusion after other causes have been considered, such as foods, medications, exercise, food and exercise, insect stings or bites, mastocytosis, C1 esterase inhibitor deficiency/dysfunction, psychogenic reactions, and Munchausen anaphylaxis (intentional surreptitious ingestion of a known allergen)
May be followed by panic attacks that can be confused with anaphylaxis
May coexist with food allergy, exercise-induced anaphylaxis, chronic urticaria, food allergy
Fatalities have been reported
Initial Approach
Besides careful history, consider:
Careful physical exam for urticaria pigmentosa
Skin testing/sIgE to foods and drugs
Fresh food prick to prick SPT may be more sensitive than commercial extracts
sIgE to galactose-alpha-1,3-galactose
Baseline and acute phase serum tryptase
Baseline and acute phase 24 h urine for histamine metabolites, prostaglandin D2
Oral challenges
Peripheral blood c-Kit D816V mutation
Bone marrow examination in some cases
Idiopathic Anaphylaxis Classification (Patterson)
Management
Patterson
Greenberger/Lieberman
Discontinue medications that may complicate treatment or worsen an event:
Beta-blockers
ACE-inhibitors and ARBs
MAO-inhibitors
Certain tricyclic antidepressants (e.g. amitryptiline)
Encourage carrying an epinephrine auto-injector and wearing identification jewelry
Initial Treatment
Refractory Treatment
Epinephrine IM
Cetirizine or other H1 antihistamine PO
Albuterol 2-4 mg PO BID (if tolerated)
Prednisone PO if episodes severe or frequent
40-60 mg PO QD x 1-2 wk, then QOD x 1 mo, then taper by 5-10 mg monthly if the patient is not experiencing anaphylaxis
Lack of response to prednisone (e.g. at least 40 mg PO QD for 2 weeks) suggests USIA subtype (see above), and treatment often paradoxically worsens this subtype
LTRA PO
Cromolyn PO
Ketotifen 2 mg PO TID - may be useful if prednisone dependent
Azathioprone or tacrolimus PO
Omalizumab (limited evidence for use in literature)
Note:
Vast majority of patients with IA gradually improve, including patients who have frequent episodes and require prednisone for months or even 2-3 years
Definition
Initial Approach
Idiopathic Anaphylaxis Classification (Patterson)
Management
Patterson
Greenberger/Lieberman
Note:
References